Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Globe Newswire (Mon, 23-Mar 4:05 PM ET)
Sutro Biopharma to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 8:30 AM ET)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Globe Newswire (Mon, 23-Feb 8:30 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Globe Newswire (Tue, 10-Feb 7:00 AM ET)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of April 7, 2026, STRO stock price climbed to $25.71 with 399,925 million shares trading.
STRO has a beta of 2.66, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.23 to the broad based SPY ETF.
STRO has a market cap of $425.94 million. This is considered a Small Cap stock.
Last quarter Sutro Biopharma reported $12 million in Revenue and -$5.29 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.77.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, IWC, PRFZ, BIB.
STRO has outperformed the market in the last year with a price return of +374.3% while the SPY ETF gained +31.9%. STRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +123.2% and +20.5%, respectively, while the SPY returned -4.5% and +0.6%, respectively.
STRO support price is $22.37 and resistance is $25.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.